Table 2.
Population characteristics
| Trial name | Age, years | Male (%) | PAF (%) | Hypertension (%) | Diabetes (%) | Prior stroke or SE (%) | ACS (%) | Elective PCI (%) | Clopidogrel (%) | Potent P2Y12 inhibitor (%) | CHA2DS2-VASc | HAS-BLED |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUGUSTUS [17] | 70.7 | 71 | NA | 88.3 | 36.4 | 13.8 | 37.3 | 38.8 | 92.6 | 7.4 | 3.9 | 2.85 |
| ENTRUST-AF PCI [18] | 69.5 | 74.4 | 50.5 | 90.3 | 34.3 | 14 | 51.6 | 48.4 | 92.4 | 7.6 | 4 | 3 |
| PIONEER AF-PCI [13] | 70.2 | 73.9 | 43.4 | NA | NA | NA | 51.9 | 48.1 | 94.7 | 5.3 | NA | NA |
| RE-DUAL PCI [14] | 70.8 | 75.96 | 49.6 | NA | 36.4 | 8.3 | 50.5 | 49.5 | 88 | 12 | 3.62 | 2.71 |
ACS acute coronary syndrome, NA not assessed, PAF paroxysmal atrial fibrillation, PCI percutaneous coronary intervention, SE systemic embolism